Group A
|
Tyrosine metabolism
|
20.7
|
8.3E-04
|
PNMT, MAOA, ADH1B, AOX1
|
Cytokine-cytokine receptor interaction
|
3.7
|
4.0E-02
|
LEP, CCL3L3, IL1R2, IL18, IFNLR1
|
Amphetamine addiction
|
8.2
|
4.9E-02
|
GRIA1, MAOA, PPP1R1B
|
Drug metabolism - cytochrome P450
|
8.0
|
5.1E-02
|
MAOA, ADH1B, AOX1
|
Neuroactive ligand-receptor interaction
|
-5.3
|
4.0E-03
|
GRIN2A, GABRA4, TACR1, GRPR, MCHR1, NTSR1
|
Cytokine-cytokine receptor interaction
|
-5.1
|
1.4E-02
|
IL1A, CSF2, IL1B, TNFRSF9, CXCR4
|
Calcium signaling pathway
|
-5.5
|
3.2E-02
|
GRIN2A, TACR1, GRPR, NTSR1
|
Salmonella infection
|
-8.9
|
4.2E-02
|
IL1A, CSF2, IL1B
|
Hematopoietic cell lineage
|
-8.5
|
4.5E-02
|
IL1A, CSF2, IL1B
|
Rheumatoid arthritis
|
-8.4
|
4.6E-02
|
IL1A, CSF2, IL1B
|
Group B
|
Drug metabolism - cytochrome P450
|
15.2
|
3.6E-05
|
ADH4, MAOA, ADH1B, ADH1A, AOX1, FMO2
|
Tyrosine metabolism
|
24.6
|
4.1E-05
|
ADH4, MAOA, ADH1B, ADH1A, AOX1
|
Retinol metabolism
|
10.7
|
5.5E-03
|
ADH4, ADH1B, ADH1A, AOX1
|
Fatty acid degradation
|
12.3
|
2.3E-02
|
ADH4, ADH1B, ADH1A
|
Glycolysis / Gluconeogenesis
|
7.7
|
5.5E-02
|
ADH4, ADH1B, ADH1A
|
Chemical carcinogenesis
|
6.4
|
7.5E-02
|
ADH4, ADH1B, ADH1A
|
Cell adhesion molecules (CAMs)
|
-4.6
|
8.6E-06
|
ICAM2, SELE, SELP, HLA-DMB, CDH3, CLDN3, CDH1, PECAM1, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DQA1, HLA-DRB1, HLA-DQB1
|
Allograft rejection
|
-8.9
|
1.1E-04
|
HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
Basal cell carcinoma
|
-6.9
|
1.3E-04
|
WNT10B, SHH, WNT10A, WNT7B, PTCH2, FZD10, WNT2, WNT4
|
Type I diabetes mellitus
|
-7.8
|
2.3E-04
|
HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
Inflammatory bowel disease (IBD)
|
-5.8
|
3.8E-04
|
HLA-DMB, RORC, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
Autoimmune thyroid disease
|
-6.3
|
7.5E-04
|
HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
Pancreatic secretion
|
-4.0
|
3.5E-03
|
CPA3, CPB1, FXYD2, KCNQ1, PLA2G2A, CLCA2, CD38, ATP1A2
|
cAMP signaling pathway
|
-2.6
|
9.2E-03
|
GRIA2, CHRM1, NPY, FXYD2, PDE3B, CNGA1, ADRB1, ATP1A2, SSTR1, SSTR2, GRIN1
|
Hippo signaling pathway
|
-2.8
|
1.5E-02
|
WNT10B, WNT10A, CDH1, WNT7B, RASSF6, FZD10, WNT2, BMP7, WNT4
|
Wnt signaling pathway
|
-2.7
|
2.7E-02
|
WNT10B, WNT10A, SFRP2, MMP7, WNT7B, FZD10, WNT2, WNT4
|
Signaling pathways regulating pluripotency of stem cells
|
-2.7
|
2.9E-02
|
WNT10B, WNT10A, WNT7B, IGF1, FZD10, WNT2, ISL1, WNT4
|
Pathways in cancer
|
-1.8
|
3.9E-02
|
WNT10B, WNT10A, WNT7B, PTCH2, CBLC, KLK3, FZD10, IGF1, MMP9, SHH, GNG4, CDH1, WNT2, NKX3-1, WNT4
|
cGMP-PKG signaling pathway
|
-2.4
|
5.1E-02
|
NOS3, FXYD2, PDE2A, PDE3B, CNGA1, ADRB1, ATP1A2, ADRA2A
|
Adrenergic signaling in cardiomyocytes
|
-2.4
|
7.3E-02
|
MYL4, TNNT2, FXYD2, KCNQ1, ADRB1, ATP1A2, CACNG4
|
Cardiac muscle contraction
|
-3.1
|
7.5E-02
|
MYL4, TNNT2, FXYD2, ATP1A2, CACNG4
|
Group C
|
Tyrosine metabolism
|
45.4
|
2E-3
|
MAOA, ADH1B, AOX1
|
Drug metabolism - cytochrome P450
|
23.3
|
6E-3
|
MAOA, ADH1B, AOX1
|
Tryptophan metabolism
|
26.5
|
6.8E-2
|
MAOA, AOX1
|
Group D
|
Cytokine-cytokine receptor interaction
|
4.5
|
5.1E-2
|
CCL3L3, IL1R2, IL18, IFNLR1
|
Neuroactive ligand-receptor interaction
|
-5.4
|
1.1E-2
|
GRIN2A, GABRA4, TACR1, GRPR, NTSR1
|
Calcium signaling pathway
|
-6.7
|
1.9E-2
|
GRIN2A, TACR1, GRPR, NTSR1
|
Salmonella infection
|
-10.8
|
2.8E-2
|
IL1A, CSF2, IL1B
|
Hematopoietic cell lineage
|
-10.3
|
3.1E-2
|
IL1A, CSF2, IL1B
|
Rheumatoid arthritis
|
-10.2
|
3.2E-2
|
IL1A, CSF2, IL1B
|
Amoebiasis
|
-8.5
|
4.4E-2
|
CSF2, SERPINB2, IL1B
|
Measles
|
-6.7
|
6.7E-2
|
IL1A, IL1B, TACR1
|
Circadian rhythm
|
-19.3
|
9.5E-2
|
PER3, NR1D1
|
Group E
|
Drug metabolism - cytochrome P450
|
10.5
|
3.1E-2
|
ADH4, ADH1A, FMO2
|
Rap1 signaling pathway
|
4.5
|
5.2E-2
|
FPR1, KDR, FGFR4, RAPGEF5
|
Cell adhesion molecules (CAMs)
|
-4.8
|
0.000
|
ICAM2, SELE, SELP, HLA-DMB, CDH3, CLDN3, CDH1, PECAM1, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DQA1, HLA-DRB1, HLA-DQB1
|
Type I diabetes mellitus
|
-8.2
|
0.000
|
HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
Antigen processing and presentation
|
-5.2
|
1E-3
|
CD74, HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
cAMP signaling pathway
|
-2.7
|
7E-3
|
GRIA2, CHRM1, NPY, FXYD2, PDE3B, CNGA1, ADRB1, ATP1A2, SSTR1, SSTR2, GRIN1
|
Proteoglycans in cancer
|
-2.7
|
7E-3
|
WNT10B, WNT10A, HPSE2, WNT7B, CBLC, IGF1, FZD10, WNT2, HOXD10, MMP9, WNT4
|
Wnt signaling pathway
|
-2.8
|
2.1E-2
|
WNT10B, WNT10A, SFRP2, MMP7, WNT7B, FZD10, WNT2, WNT4
|
Signaling pathways regulating pluripotency of stem cells
|
-2.8
|
2.3E-2
|
WNT10B, WNT10A, WNT7B, IGF1, FZD10, WNT2, ISL1, WNT4
|
Pathways in cancer
|
-1.9
|
2.7E-2
|
WNT10B, WNT10A, WNT7B, PTCH2, CBLC, KLK3, FZD10, IGF1, MMP9, SHH, GNG4, CDH1, WNT2, NKX3-1, WNT4
|
Phagosome
|
-2.6
|
3.2E-2
|
HLA-DMB, SFTPA2, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1
|
Hippo signaling pathway
|
-2.6
|
3.3E-2
|
WNT10B, WNT10A, CDH1, WNT7B, FZD10, WNT2, BMP7, WNT4
|
cGMP-PKG signaling pathway
|
-2.5
|
4.1E-2
|
NOS3, FXYD2, PDE2A, PDE3B, CNGA1, ADRB1, ATP1A2, ADRA2A
|
Adrenergic signaling in cardiomyocytes
|
-2.5
|
6E-2
|
MYL4, TNNT2, FXYD2, KCNQ1, ADRB1, ATP1A2, CACNG4
|
Cardiac muscle contraction
|
-3.3
|
6.5E-2
|
MYL4, TNNT2, FXYD2, ATP1A2, CACNG4
|
Dilated cardiomyopathy
|
-2.9
|
9E-2
|
DES, TNNT2, ADRB1, IGF1, CACNG4
|